Wellington reports 8.57% stake in Soleno Therapeutics
Soleno Therapeutics, Inc. beneficial ownership disclosure amended by Wellington affiliates.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Soleno Therapeutics, Inc. beneficial ownership disclosure amended by Wellington affiliates. The filing reports Wellington-related entities collectively beneficially own 4,426,781 shares, representing 8.57% of Soleno's common stock. Ownership is held for clients of Wellington investment advisers; voting and dispositive powers are largely shared across the named entities.
Insights
Wellington holds a meaningful passive stake reported under Schedule 13G/A.
Wellington Management Group LLP and affiliated entities report beneficial ownership of 4,426,781 shares (8.57%). The position is held for clients of multiple Wellington investment advisers and is reported as shared voting and dispositive power among affiliated entities.
Filing indicates passive, advisory-held ownership rather than direct corporate control; subsequent filings would disclose material changes in percent ownership or changes in voting/dispositive arrangements.
Disclosure aligns with Schedule 13G/A rules for institutional investors.
The cover responses and Item 7 detail the parent/subsidiary and adviser structure: Wellington Management Group LLP > Wellington Group Holdings LLP > Wellington Investment Advisors Holdings LLP, with multiple Wellington Investment Advisers listed. Signatures by a Compliance Manager are provided.
Investors can treat this as an institutional disclosure; any shift to active intent would require Schedule 13D filing.
Key Figures
Key Terms
Schedule 13G/A regulatory
beneficially owned regulatory
investment adviser (IA) regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Wellington report in Soleno Therapeutics (SLNO)?
Which Wellington entities are named on the Schedule 13G/A for SLNO?
Does the filing show sole voting or dispositive power for Wellington?
Are the Wellington holdings held on behalf of other named parties?
What item confirms the corporate structure and adviser relationships?
AI-generated analysis. How Rhea-AI works. Not financial advice.